US healthtech firm Omega Ophthalmics is developing implanted lenses that would create a platform for augmented reality inside the human eye. The company, currently awaiting approval from the US Food and Drug Administration as well as European regulators, has successfully carried out a small-scale clinical trial over the past six months with no ill-effects. In this case, however, the lens was inserted into an eye in which there were two types of retinal disease: one caused by damage to the retina's photoreceptors, called cones, while another type resulted from
US healthtech firm Omega Ophthalmics is developing implanted lenses that would create a platform for augmented reality inside the human eye. The company, currently awaiting approval from the US Food and Drug Administration as well as European regulators, has successfully carried out a small-scale clinical trial over the past six months with no ill-effects. Co-founder Gary Wortz said the space could offer manufacturers the opportunity to add "different interactive sensors, drug delivery devices and the inclusion of augmented and virtual reality integration".